Amylyx Pharmaceuticals prices upsized $500M public offering of common stock

General Counsel Martin Wilson of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) divested 631 shares of the company's common stock on August 18, 2026, generating proceeds of $2,133. The transaction was executed to fulfill tax withholding requirements related to the vesting of Restricted Stock Units (RSUs). After this sale, Mr. Wilson holds 673,853 shares of Rocket Pharmaceuticals common stock.

The firm's RSUs convert to common stock on a one-to-one basis. The company's shares are currently trading at $3.48, resulting in a market capitalization of $383 million. InvestingPro analysis suggests Rocket Pharmaceuticals may be undervalued at present, placing it among promising stocks on the platform's undervalued list. The company is noted to have more cash than debt on its balance sheet, although it is rapidly depleting its cash reserves.

Earlier this year, Rocket Pharmaceuticals successfully sold its Rare Pediatric Disease Priority Review Voucher for $180 million, a voucher granted by the FDA in March 2026 in connection with the approval of KRESLADI, a gene therapy for severe leukocyte adhesion deficiency-I. At the company's 2026 Annual Meeting of Stockholders, shareholders elected seven directors, including Peter Fong, M.D., and Carsten Boess.

TD Cowen has maintained a Hold rating on Rocket Pharmaceuticals, citing the lack of safety events in the initial three patients treated with the recalibrated dose of RP-A501 gene therapy for Danon disease.